| 000 | 01857 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514193034.0 | ||
| 264 | 0 | _c20041001 | |
| 008 | 200410s 0 0 eng d | ||
| 022 | _a0959-4965 | ||
| 024 | 7 |
_a10.1097/01.wnr.0000127461.15985.07 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKrishnamurthi, Rita | |
| 245 | 0 | 0 |
_aN-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats. _h[electronic resource] |
| 260 |
_bNeuroreport _cJul 2004 |
||
| 300 |
_a1601-4 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBehavior, Animal _xdrug effects |
| 650 | 0 | 4 |
_aCell Count _xmethods |
| 650 | 0 | 4 |
_aCorpus Striatum _xinjuries |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFunctional Laterality |
| 650 | 0 | 4 |
_aImmunohistochemistry _xmethods |
| 650 | 0 | 4 |
_aInsulin-Like Growth Factor I _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aOligopeptides _xtherapeutic use |
| 650 | 0 | 4 |
_aOxidopamine _xtoxicity |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aPsychomotor Performance _xdrug effects |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 | _aRotation |
| 650 | 0 | 4 |
_aSubstantia Nigra _xinjuries |
| 650 | 0 | 4 |
_aSympatholytics _xtoxicity |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTyrosine 3-Monooxygenase _xmetabolism |
| 700 | 1 | _aStott, Simon | |
| 700 | 1 | _aMaingay, Matt | |
| 700 | 1 | _aFaull, Richard L M | |
| 700 | 1 | _aMcCarthy, Dianne | |
| 700 | 1 | _aGluckman, P | |
| 700 | 1 | _aGuan, J | |
| 773 | 0 |
_tNeuroreport _gvol. 15 _gno. 10 _gp. 1601-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/01.wnr.0000127461.15985.07 _zAvailable from publisher's website |
| 999 |
_c14936460 _d14936460 |
||